News & Events
Summa Equity Acquires Sengenics to Advance Precision Medicine through Proteomics
Sengenics Launches ImmuSAFE COVID+, the World’s First High-Throughput, Multi-Antigen COVID-19 Biochip Test
Sengenics Announces New Research Collaboration with GSK Focusing on Immunology
Sengenics Successfully Produces Functional COVID-19 Antigens and Makes Them Available for Research and Vaccine Development
Sengenics, a Leading Precision Medicine Focused Company, to Present at the Annual BIO CEO and Investor Conference
Sengenics, a Leading Commercial Stage Precision Medicine Focused Company, which Enables Pharma Companies to Identify Drug Responders, to Present at Biotech Showcase™ 2020
Renal Cancer Research by Sengenics and the University of Leeds Awarded Early Detection Primer Grant Funding from Cancer Research UK
Sengenics Partners with the Foundation for the National Institutes of Health Biomarkers Consortium
Sengenics Partners with Olivia Newton-John Cancer Research Institute to Enhance Safety of Cancer Immunotherapy Drugs
"*" indicates required fields
By proceeding, I agree to Sengenics’ Terms of Use and acknowledge that I have read the Privacy Policy. I also agree that Sengenics or its representatives may contact me by email at the email address I provide, including for marketing purposes.
Δ
"*" Indicates required fields By proceeding, I agree to Sengenics’ Terms of Use and acknowledge that I have read the Privacy Policy. I also agree that Sengenics or its representatives may contact me by email at the email address I provide, including for marketing purposes.
